CD274 and non-small cell lung carcinoma: Consequently, in a sample of 200 advanced NSCLC patients who received single anti-PD-1/PD-L1, Yang et al. assessed 1633 CT scans and 3414 blood samples, including serial radiomics, laboratory data and baseline clinical data, to build deep learning models useful for the selection and identification of responders and non-responders to immunotherapy.